The end of high drug prices? Exploring the potential and limits of PDABs
Certain states in the US have enacted or are actively considering legislation to create PDABs, Prescription Drug Affordability Boards. PDABs are independent...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Rhett Johnson has over 25 years of consulting experience, assisting life sciences clients develop commercialization strategies that generate a sustainable competitive advantage in a complex and constantly evolving healthcare marketplace. Areas of focus include corporate growth strategy, asset evaluations and product strategy, pricing and market access, analytics and forecasting, and competitive analysis.
Mr. Johnson joined CRA as an Associate after studying economics at the University of Chicago. Mr. Johnson now co-leads CRAs Global Life Sciences Strategy Consulting team, with responsibility for innovation and practice growth.